Global Cushing's Disease Market, By Treatment Type (Surgery, Radiation Therapy, Drugs, Others), Diagnosis (Petrosal Sinus Sampling, Saliva Test, Urine and Blood Tests, Imaging Tests), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
In recent years, the Cushing's disease market is anticipated to grow rapidly during the forecast period. Cushing's syndrome is a group of symptoms brought on by a high hormone cortisol level. The syndrome, also known as hypercortisolism, is frequently induced by corticosteroid medication adverse effects. Inflammation and autoimmune diseases are commonly treated with corticosteroids. Iatrogenic Cushing's syndrome and endogenous Cushing's syndrome are the two kinds of Cushing's syndrome. Weight gain, adipose tissue deposits around the abdomen and back, purple stretch marks, thinner skin that is easily bruised, acne, and other symptoms are common.
Data Bridge Market Research analyses that the Cushing's disease market was valued at USD 333.80 million in 2021 and is expected to reach USD 686.89 million by 2029, registering a CAGR of 9.44% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
High blood pressure, reddish stretch marks, abdominal obesity, round red face, weak muscles, weak bones, a fat mass between the shoulders, and delicate skin that heals slowly are all symptoms and indicators of Cushing's syndrome. Cushing's syndrome is caused by two main factors: excessive cortisol-like medicines like prednisone, and tumours formed by adrenal glands overproducing cortisol. Other tumors, such as those linked to hereditary illnesses including multiple endocrine neoplasia type 1 and Carney complex, may potentially be responsible for this condition. In most situations, a combination of surgery, radiation, and chemotherapy can be used to treat and cure the condition.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment Type (Surgery, Radiation Therapy, Drugs, Others), Diagnosis (Petrosal Sinus Sampling, Saliva Test, Urine and Blood Tests, Imaging Tests), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Zydus Cadila (India), AstraZeneca (UK), Johnson & Johnson (US), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Strides Pharma Science Limited (India), Cipla Inc. (US), LEO Pharma A/S (Denmark), Aurobindo Pharma (India), Lupin (India), Hikma Pharmaceuticals PLC (UK)
|
|
Market Opportunities
|
|
Cushing's Disease Market Dynamics
Drivers
- Increasing prevalence of Cushing's disease
The rising prevalence of Cushing's disease is estimated to enhance the market's growth. Cushing's syndrome is expected to have a yearly incidence of 1–3 cases per million inhabitants, according to the Orphanet Journal of Rare Disease, but its frequency was close to 40 cases per million inhabitants in 2012. Cushing's syndrome, also known as hypercortisolism, is a hormonal condition characterized by continuous exposure of bodily tissue to excessive quantities of the hormone cortisol. Cushing's syndrome affects adults between the ages of 20 and 50.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of Cushing's disease market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
- Growing number of geriatric population
The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to get Cushing's disease, further estimated to enhance the market's growth rate. Cushing's disease is uncommon, however, it is at risk of developing in obese patients with type 2 diabetes, high blood pressure, and poorly regulated blood glucose.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the Cushing's disease market. Additionally, changing lifestyles of people and rising level of disposable income will result in the expansion of Cushing's disease market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the Cushing's disease market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate.
Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for Cushing's disease market growth during the forecast period.
Restraints/Challenges
On the other hand, high cost high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the Cushing's disease market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.
This Cushing's disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Cushing's disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Cushing's disease market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Cushing's Disease Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The Cushing's disease market was hampered by the supply chain slowness.
Recent Development
- In March 2020, the U.S. Food and Drug Administration (FDA) announced the approval of Isturisa (osilodrostat) oral tablets for adults suffering from Cushing's disease who cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease. Isturisa is the first FDA-approved medicine to directly target cortisol overproduction by inhibiting the enzyme 11-beta-hydroxylase and stopping cortisol manufacture.
Global Cushing's Disease Market Scope
The Cushing's disease market is segmented on the basis of treatment type, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment Type
- Surgery
- Radiation Therapy
- Drugs
- Ketoconazole
- Mitotane
- Aminoglutethimide
- Metyrapone
- Mifepristone
- Etomidate
- Pasireotide
- Others
Diagnosis
- Petrosal Sinus Sampling
- Saliva Test
- Urine and Blood Tests
- Imaging Tests
- Computerized tomography (CT) scans
- Magnetic resonance imaging (MRI)
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Cushing's Disease Market Regional Analysis/Insights
The Cushing's disease market is analysed and market size insights and trends are provided by country, treatment type, diagnosis, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Cushing's disease market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the Cushing's disease market because of the rising number of research activities and the growing prevalence of obesity population in this region. Additionally, rising healthcare expenditure and favorable government policies will further propel the market's growth rate in this region.
Asia-Pacific are expected to grow during the forecast period due to the increasing level of disposable income in this region. Also, the development of healthcare infrastructure and rising awareness about the diseases will further propel the market's growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Cushing's Disease Market Share Analysis
The Cushing's disease market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Cushing's disease market.
Some of the major players operating in the Cushing's disease market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd.(Israel)
- Sanofi (France)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Zydus Cadila (India)
- AstraZeneca (UK)
- Johnson & Johnson (US)
- Bayer AG (Germany)
- Sun Pharmaceutical Industries Ltd. (India)
- Bristol-Myers Squibb Company (US)
- Eli Lilly and Company (US)
- Strides Pharma Science Limited (India)
- Cipla Inc. (US)
- LEO Pharma A/S (Denmark)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (UK)
SKU-